Weekly Investment Analysts’ Ratings Changes for Revance Therapeutics (RVNC)

A number of firms have modified their ratings and price targets on shares of Revance Therapeutics (NASDAQ: RVNC) recently:

  • 12/6/2017 – Revance Therapeutics had its price target raised by analysts at Mizuho from $37.00 to $54.00. They now have a “buy” rating on the stock.
  • 12/5/2017 – Revance Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $42.00 price target on the stock.
  • 12/5/2017 – Revance Therapeutics had its price target raised by analysts at Piper Jaffray Companies from $28.00 to $51.00. They now have an “overweight” rating on the stock.
  • 12/5/2017 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/4/2017 – Revance Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/29/2017 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/27/2017 – Revance Therapeutics is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $31.00 price target on the stock.
  • 11/16/2017 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/16/2017 – Revance Therapeutics is now covered by analysts at Mizuho. They set a “buy” rating and a $37.00 price target on the stock.
  • 10/27/2017 – Revance Therapeutics had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $28.00 price target on the stock.
  • 10/24/2017 – Revance Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “RT002 injectable has the potential to be a longer lasting, safe alternative to the current products on the market, including the market leader, Botox. If RVNC can successfully develop RT002, we continue to expect the company could be in a position to submit a BLA in 2019, with a potential approval and launch in 2019/2020.””
  • 10/11/2017 – Revance Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. “

Revance Therapeutics Inc (NASDAQ RVNC) traded down $1.10 during midday trading on Wednesday, hitting $33.65. 2,239,993 shares of the company traded hands, compared to its average volume of 226,904. Revance Therapeutics Inc has a 1 year low of $15.85 and a 1 year high of $37.20.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.06). The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.64) EPS. analysts forecast that Revance Therapeutics Inc will post -3.73 earnings per share for the current year.

In other news, Director Mark J. Foley acquired 20,000 shares of Revance Therapeutics stock in a transaction that occurred on Tuesday, November 7th. The stock was purchased at an average price of $26.96 per share, for a total transaction of $539,200.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $161,760. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO L Daniel Browne sold 7,600 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $23.58, for a total transaction of $179,208.00. Following the transaction, the chief executive officer now owns 148,450 shares of the company’s stock, valued at approximately $3,500,451. The disclosure for this sale can be found here. In the last quarter, insiders have sold 44,026 shares of company stock valued at $1,135,234. 18.86% of the stock is currently owned by company insiders.

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.